默沙东Remigromig在糖尿病性黄斑水肿关键性2B/3期Brunello研究中达到主要终点——该药物为Wnt通路三特异性激动剂

美股速递
Sep 24

默沙东旗下药物Remigromig——一种靶向无翅相关整合位点(Wnt)通路的三特异性激动剂——在针对成人糖尿病性黄斑水肿的关键性2B/3期Brunello研究中成功触及主要终点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10